FeesSafety
Pluang+

iShares J.P. Morgan EM High Yield Bond ETF rated 'Hold' due to muted real return outlook amid inflation.

Market News
22 Oct 2026
Seeking Alpha
View Source
Neutral
iShares J.P. Morgan EM High Yield Bond ETF rated 'Hold' due to muted real return outlook amid inflation.

The iShares J.P. Morgan EM High Yield Bond ETF (EMHY) is currently rated as 'Hold' because its expected real returns are muted given the current inflation environment. The ETF yields 8.27% with a duration of 4.62 years, but about half of its portfolio is sensitive to interest rates and oil prices, which adds risk. Scenario analysis suggests likely returns between 3% and 7%, with real returns close to zero after adjusting for inflation. Despite this, EMHY offers a better risk/return profile compared to similar U.S. high yield bond alternatives, making it a cautious option for investors seeking income with moderate risk.

The iShares J.P. Morgan EM High Yield Bond ETF (EMHY) is discussed with its 8.27% yield and 0% real return in the current inflation context. For readers following US stocks on Pluang, here is the market snapshot as of Oct 22, 2026 09:41 WIB: out of 150 priced stocks, 64 rose and 86 fell. Notable movers include AT&T Inc. (T) at USD 22.04 with a 1-day change of -6.01% and a typical hold time of 118 days, JD.Com Inc (JD) at USD 25.16 down 5.98%, and Netflix Inc (NFLX) at USD 65.07 down 5.23%.

More News

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, a key infrastructure initiative aimed at strengthening the electricity network's security and resilience in the Balearic Islands. ...

Market News
Bullish
51 minutes ago
Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics...

Company Fundamentals
Bullish
51 minutes ago
Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen reported a 24.6% sales growth at constant exchange rates for the first nine months of 2026, driven by strong performance in Oncology, Rare Disease, and Neuroscience segments. The company upgraded its full-year sales growth guidance to around 23...

Company Fundamentals
Bullish
51 minutes ago
Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, aimed at enhancing the electricity network's security and resilience in the Balearic Islands. The project includes a six-month eng...

Market News
Bullish
51 minutes ago
Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans posted a 10.1% increase in revenue to €4.95 billion for the first nine months of 2026, driven by strong organic growth in its electrification segments PWR-Grid and PWR-Connect. The company successfully integrated Republic Wire in the US and co...

Company Fundamentals
Bullish
51 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App